|
1
|
Weitz J, Koch M, Debus J, Höhler T, Galle
PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005.
View Article : Google Scholar
|
|
2
|
O’Reilly DA and Poston GJ: Colorectal
liver metastases: current and future perspectives. Future Oncol.
2:525–531. 2006.
|
|
3
|
Rodgers MS and McCall JL: Surgery for
colorectal liver metastases with hepatic lymph node involvement: a
systematic review. Br J Surg. 87:1142–1155. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martin LW and Warren RS: Current
management of colorectal liver metastases. Surg Oncol Clin North
Am. 9:853–876. 2000.PubMed/NCBI
|
|
5
|
Penna C and Nordlinger B: Colorectal
metastasis (liver and lung). Surg Clin North Am. 82:1075–1090.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kato T, Yasui K, Hirai T, Kanemitsu Y,
Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results
for hepatic metastasis of colorectal cancer with special reference
to effectiveness of hepatectomy: analysis of prognostic factors for
763 cases recorded at 18 institutions. Dis Colon Rectum.
46:S22–S31. 2003.PubMed/NCBI
|
|
7
|
Nordlinger B, Guiguet M, Vaillant JC,
Balladur P, Boudjema K, Bachellier P and Jaeck D: Surgical
resection of colorectal carcinoma metastases to the liver: a
prognostic scoring system to improve case selection, based on 1568
patients. Cancer. 77:1254–1262. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seifert JK, Böttger TC, Weigel TF, Gönner
U and Junginger T: Prognostic factors following liver resection for
hepatic metastases from colorectal cancer. Hepatogastroenterology.
47:239–246. 2000.PubMed/NCBI
|
|
9
|
Fong Y, Fortner J, Sun RL, Brennan MF and
Blumgart LH: Clinical score for predicting recurrence after hepatic
resection for metastatic colorectal cancer: analysis of 1001
consecutive cases. Ann Surg. 230:309–321. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Minagawa M, Makuuchi M, Torzilli G,
Takayama T, Kawasaki S, Kosuge T, Yamamoto J and Imamura H:
Extension of the frontiers of surgical indications in the treatment
of liver metastases from colorectal cancer: long-term results. Ann
Surg. 231:487–499. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jonas S, Thelen A, Benckert C, Spinelli A,
Sammain S, Neumann U, Rudolph B and Neuhaus P: Extended resections
of liver metastases from colorectal cancer. World J Surg.
31:511–521. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jaeck D, Oussoultzoglou E, Rosso E, Greget
M, Weber JC and Bachellier P: A two-stage hepatectomy procedure
combined with portal vein embolization to achieve curative
resection for initially unresectable multiple and bilobar
colorectal liver metastases. Ann Surg. 240:1037–1049. 2004.
View Article : Google Scholar
|
|
13
|
Wood CB, Gillis CR and Blumgart LH: A
retrospective study of the natural history of patients with liver
metastases from colorectal cancer. Clin Oncol. 2:285–288.
1976.PubMed/NCBI
|
|
14
|
Wagner JS, Adson MA, Van Heerden JA, Adson
MH and Ilstrup DM: The natural history of hepatic metastases from
colorectal cancer: a comparison with resective treatment. Ann Surg.
199:502–508. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McMillan DC: An inflammation-based
prognostic score and its role in the nutrition-based management of
patients with cancer. Proc Nutr Soc. 67:257–262. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McMillan DC, Crozier JE, Canna K, Angerson
WJ and McArdle CS: Evaluation of an inflammation-based prognostic
score (GPS) in patients undergoing resection for colon and rectal
cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Japanese Society for Cancer of the Colon
and Rectum. Japanese classification of colorectal carcinoma. 1st
English ed. Kanehara Co., Ltd.; Tokyo: 1997
|
|
18
|
Sobin LH and Wittekind: UICC TNM
classification of malignant tumors. 5th edition. John Wiley &
Sons, Inc; New York: 1997
|
|
19
|
Jaeck D, Bachellier P, Guiguet M, Boudjema
K, Vaillant JC, Balladur P and Nordlinger B: Long-term survival
following resection of colorectal hepatic metastases. Association
Française de Chirurgie. Br J Surg. 84:977–980. 1997.PubMed/NCBI
|
|
20
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic
scores based on the systemic inflammatory response in patients with
inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Comparison of an inflammation-based
prognostic score (GPS) with performance status (ECOG) in patients
receiving platinum-based chemotherapy for inoperable non-small-cell
lung cancer. Br J Cancer. 90:1704–1706. 2004.PubMed/NCBI
|
|
22
|
Al Murri AM, Bartlett JM, Canney PA,
Doughty JC, Wilson C and McMillan DC: Evaluation of an
inflammation-based prognostic score (GPS) in patients with
metastatic breast cancer. Br J Cancer. 94:227–230. 2006.PubMed/NCBI
|
|
23
|
Crumley AB, McMillan DC, McKernan M,
McDonald AC and Stuart RC: Evaluation of an inflammation-based
prognostic score in patients with inoperable gastro-oesophageal
cancer. Br J Cancer. 94:637–641. 2006.PubMed/NCBI
|
|
24
|
Glen P, Jamieson NB, McMillan DC, Carter
R, Imrie CW and McKay CJ: Evaluation of an inflammation-based
prognostic score in patients with inoperable pancreatic cancer.
Pancreatology. 6:450–453. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ramsey S, Lamb GW, Aitchison M, Graham J
and McMillan DC: Evaluation of an inflammation-based prognostic
score in patients with metastatic renal cancer. Cancer.
109:205–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leitch EF, Chakrabarti M, Crozier JE,
McKee RF, Anderson JH, Horgan PG and McMillan DC: Comparison of the
prognostic value of selected markers of the systemic inflammatory
response in patients with colorectal cancer. Br J Cancer.
97:1266–1270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saltz LB, Cox JV, Blanke C, Rosen LS,
Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta
N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and
leucovorin for metastatic colorectal cancer. Irinotecan Study
Group. N Engl J Med. 343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: a multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Gramont A, Vignoud J, Tournigand C,
Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N and
Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil
48-hour continuous infusion in pretreated metastatic colorectal
cancer. Eur J Cancer. 33:214–219. 1997.
|
|
30
|
Poston GJ: The use of irinotecan and
oxaliplatin in the treatment of advanced colorectal cancer. Eur J
Surg Oncol. 31:325–330. 2005. View Article : Google Scholar : PubMed/NCBI
|
